Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Patient Registry to Evaluate the Real-world Safety of Ruconest® (C1 Esterase Inhibitor [Recombinant]) for the Treatment of Hereditary Angioedema

NCT03697187 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT03697187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Patient Registry to Evaluate the Real-world Safety of Ruconest® (C1 Esterase Inhibitor [Recombinant]) for the Treatment of Hereditary Angioedema
Lead sponsor
Pharming Technologies B.V.
Phase
Observational
Overall status
Completed
Start date
June 30, 2018
Completion date
July 31, 2021
Enrollment
152 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema